This has been hypothesized to enhance immune checkpoint blockade in ovarian carcinoma.31 The DNA damage and increased TILs in RB1-mutant patients are plausible explanations for the increased survival in this subtype of GBM IDH-WT (Figure 4). The gene discussed is RB1; the disease is ovarian carcinoma.